skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Reduction of C-reactive protein and the use of anti-hypertensives

(2051) Views  (601) Full article downloads

Authors: Carmine Savoia, Ernesto L Schiffrin

Published Date January 2007 Volume 2007:3(6) Pages 975 - 983
DOI: http://dx.doi.org/10.2147/VHRM.S

Carmine Savoia, Ernesto L Schiffrin

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC, Canada

Abstract: Inflammatory processes are increasingly recognized as important participants in the pathophysiology of hypertension and cardiovascular disease. Angiotensin II may be to a large degree responsible for triggering vascular inflammation by inducing oxidative stress, resulting in up-regulation of inflammatory mediators. Inflammatory markers such as C-reactive protein are increased in the blood of patients with hypertension and predict the development of cardiovascular disease. Moreover, C-reactive protein may be a pro-inflammatory molecule under certain circumstances. C-reactive protein and high blood pressure in combination have additional predictive value for cardiovascular outcomes, as they contribute as independent determinants of cardiovascular risk. Therapeutic intervention aimed to reduce vascular inflammation in hypertensive patients has been proposed. Recent lines of evidence suggest that lifestyle modification and pharmacological approaches may reduce blood pressure and inflammation in patients with hypertension. Antagonism of the renin-angiotensin system with the selective angiotensin receptor blockers may improve cardiovascular outcome beyond blood pressure control, by reducing vascular inflammation and remodeling.

Keywords: vascular inflammation, hypertension, ARBs








Readers of this article also read:

Isolated periaortitis: Clinical and imaging characteristics
Acute management of poor condition subarachnoid hemorrhage patients
Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: The Indian Atherosclerosis Research Study
Rationale for multiple risk intervention: The need to move from theory to practice
Review of bosentan in the management of pulmonary arterial hypertension
Profile of etravirine for the treatment of HIV infection
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
“Integrated knowledge translation” for globally oriented public health practitioners and scientists: Framing together a sustainable transfrontier knowledge translation vision
Necessary alternatives: patients’ views of asthma treatment
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University